非典型帕金森病的生物学驱动诊断。

IF 2 Q3 CLINICAL NEUROLOGY
NeuroSci Pub Date : 2025-10-21 DOI:10.3390/neurosci6040107
Oscar Arias-Carrión, Elizabeth Romero-Gutiérrez, Emmanuel Ortega-Robles
{"title":"非典型帕金森病的生物学驱动诊断。","authors":"Oscar Arias-Carrión, Elizabeth Romero-Gutiérrez, Emmanuel Ortega-Robles","doi":"10.3390/neurosci6040107","DOIUrl":null,"url":null,"abstract":"<p><p>Atypical parkinsonian disorders-progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA)-are rare, rapidly progressive neurodegenerative syndromes characterized by distinct molecular pathologies, heterogeneous clinical phenotypes, and limited therapeutic options. Accurate diagnosis remains a major clinical challenge, especially during early and prodromal phases, due to overlap with Parkinson's disease (PD), phenotypic evolution, and the absence of reliable stand-alone biomarkers. Misclassification delays prognosis, impairs patient care, and hinders clinical trial design. This review synthesizes advances from 2015 to 2025 in clinical, imaging, and biomarker-based diagnosis of PSP, CBD, and MSA. We examine their phenotypic spectra, neuropathological substrates, and epidemiological trends, and critically evaluate the diagnostic performance and translational potential of emerging tools-including quantitative MRI morphometry, second-generation tau and α-synuclein PET ligands, neurophysiological markers such as video-oculography and autonomic testing, and fluid biomarkers such as neurofilament light chain. Persistent diagnostic barriers are identified, from phenotypic mimicry and pathological pleomorphism to the limited specificity of molecular assays and inequitable access to advanced technologies. We propose tiered, multimodal diagnostic algorithms that integrate structured clinical phenotyping with quantitative imaging, molecular diagnostics, systemic risk profiling, and autopsy-linked validation. Such biology-anchored approaches could enable diagnosis years before classical features emerge, improve patient stratification for disease-modifying trials, and lay the foundation for precision medicine in atypical parkinsonian disorders. A paradigm shift from descriptive nosology to mechanistically grounded frameworks is essential to accelerate early intervention and transform the clinical management of these devastating diseases.</p>","PeriodicalId":74294,"journal":{"name":"NeuroSci","volume":"6 4","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12551117/pdf/","citationCount":"0","resultStr":"{\"title\":\"Toward Biology-Driven Diagnosis of Atypical Parkinsonian Disorders.\",\"authors\":\"Oscar Arias-Carrión, Elizabeth Romero-Gutiérrez, Emmanuel Ortega-Robles\",\"doi\":\"10.3390/neurosci6040107\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Atypical parkinsonian disorders-progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA)-are rare, rapidly progressive neurodegenerative syndromes characterized by distinct molecular pathologies, heterogeneous clinical phenotypes, and limited therapeutic options. Accurate diagnosis remains a major clinical challenge, especially during early and prodromal phases, due to overlap with Parkinson's disease (PD), phenotypic evolution, and the absence of reliable stand-alone biomarkers. Misclassification delays prognosis, impairs patient care, and hinders clinical trial design. This review synthesizes advances from 2015 to 2025 in clinical, imaging, and biomarker-based diagnosis of PSP, CBD, and MSA. We examine their phenotypic spectra, neuropathological substrates, and epidemiological trends, and critically evaluate the diagnostic performance and translational potential of emerging tools-including quantitative MRI morphometry, second-generation tau and α-synuclein PET ligands, neurophysiological markers such as video-oculography and autonomic testing, and fluid biomarkers such as neurofilament light chain. Persistent diagnostic barriers are identified, from phenotypic mimicry and pathological pleomorphism to the limited specificity of molecular assays and inequitable access to advanced technologies. We propose tiered, multimodal diagnostic algorithms that integrate structured clinical phenotyping with quantitative imaging, molecular diagnostics, systemic risk profiling, and autopsy-linked validation. Such biology-anchored approaches could enable diagnosis years before classical features emerge, improve patient stratification for disease-modifying trials, and lay the foundation for precision medicine in atypical parkinsonian disorders. A paradigm shift from descriptive nosology to mechanistically grounded frameworks is essential to accelerate early intervention and transform the clinical management of these devastating diseases.</p>\",\"PeriodicalId\":74294,\"journal\":{\"name\":\"NeuroSci\",\"volume\":\"6 4\",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-10-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12551117/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NeuroSci\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/neurosci6040107\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroSci","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/neurosci6040107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

非典型帕金森病-进行性核上性麻痹(PSP),皮质基底变性(CBD)和多系统萎缩(MSA)-是罕见的,快速进展的神经退行性综合征,其特征是不同的分子病理,异质性临床表型和有限的治疗选择。由于与帕金森病(PD)重叠、表型进化以及缺乏可靠的独立生物标志物,准确诊断仍然是一个主要的临床挑战,特别是在早期和前驱期。错误分类延迟预后,损害患者护理,并妨碍临床试验设计。本文综述了2015年至2025年在PSP、CBD和MSA的临床、影像学和基于生物标志物的诊断方面的进展。我们研究了它们的表型谱、神经病理底物和流行病学趋势,并批判性地评估了新兴工具的诊断性能和转化潜力,包括定量MRI形态测定法、第二代tau和α-突触核蛋白PET配体、神经生理标志物(如视频眼摄影和自主神经测试)和液体生物标志物(如神经丝轻链)。从表型模仿和病理多形性到分子检测的有限特异性和获取先进技术的不公平,确定了持续存在的诊断障碍。我们提出分层、多模态的诊断算法,将结构化临床表型与定量成像、分子诊断、系统风险分析和尸检相关验证相结合。这种以生物学为基础的方法可以在经典特征出现前几年进行诊断,改善疾病改善试验的患者分层,并为非典型帕金森病的精准医学奠定基础。从描述性疾病分类学到机械基础框架的范式转变对于加速早期干预和改变这些毁灭性疾病的临床管理至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Toward Biology-Driven Diagnosis of Atypical Parkinsonian Disorders.

Atypical parkinsonian disorders-progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA)-are rare, rapidly progressive neurodegenerative syndromes characterized by distinct molecular pathologies, heterogeneous clinical phenotypes, and limited therapeutic options. Accurate diagnosis remains a major clinical challenge, especially during early and prodromal phases, due to overlap with Parkinson's disease (PD), phenotypic evolution, and the absence of reliable stand-alone biomarkers. Misclassification delays prognosis, impairs patient care, and hinders clinical trial design. This review synthesizes advances from 2015 to 2025 in clinical, imaging, and biomarker-based diagnosis of PSP, CBD, and MSA. We examine their phenotypic spectra, neuropathological substrates, and epidemiological trends, and critically evaluate the diagnostic performance and translational potential of emerging tools-including quantitative MRI morphometry, second-generation tau and α-synuclein PET ligands, neurophysiological markers such as video-oculography and autonomic testing, and fluid biomarkers such as neurofilament light chain. Persistent diagnostic barriers are identified, from phenotypic mimicry and pathological pleomorphism to the limited specificity of molecular assays and inequitable access to advanced technologies. We propose tiered, multimodal diagnostic algorithms that integrate structured clinical phenotyping with quantitative imaging, molecular diagnostics, systemic risk profiling, and autopsy-linked validation. Such biology-anchored approaches could enable diagnosis years before classical features emerge, improve patient stratification for disease-modifying trials, and lay the foundation for precision medicine in atypical parkinsonian disorders. A paradigm shift from descriptive nosology to mechanistically grounded frameworks is essential to accelerate early intervention and transform the clinical management of these devastating diseases.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
审稿时长
11 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信